What could go wrong with Codere CDRO stock Q4 2022 Profit Disappoints Biogen Inc BIIB Structural Headwinds Justify Avoidance Despite Current Profitability SILO Silo Pharma rises 557 percent despite reporting a wider than expected Q4 2023 per share loss